Detailed Narrative
Q2 FY26 Financial Performance and H1 Overview
Balaji Amines reported a Q2 FY26 consolidated revenue of INR341 crores, a slight decrease from INR358 crores in Q1 FY26. EBITDA for the quarter was INR67 crores, with margins improving to 19% from 17% in the previous quarter, while PAT remained stable at INR37 crores. For the first half of FY26, consolidated revenue stood at INR715 crores, with an EBITDA of INR131 crores and a PAT of INR74 crores, reflecting an 18% EBITDA margin and 10% PAT margin. The company maintained a zero-debt position and healthy cash management.
Volume Performance Across Product Categories
Total operational volumes for Q2 FY26 were 26,165 metric tons, maintaining a steady year-on-year level. This was broken down into 7,685 metric tons for amines, 8,374 metric tons for amines derivatives, and 10,107 metric tons for specialty chemicals. Despite a mixed operating environment and moderated demand in select pharma and agrichem segments, the diversified product portfolio helped sustain volumes.
Strategic Capacity Expansion and Commissioning Updates
The company is on track with several key projects. The DME plant is expected to be commissioned within 2-3 weeks, pending cylinder approval. N-Methyl Morpholine is slated for commissioning by the end of Q3 FY26, and Dimethyl Carbonate (DMC) by Q4 FY26 or early Q1 FY27. The Unit 1 brownfield expansion for EDA-based products is targeted for September 2026, and the Unit 2 greenfield project at Chincholi by December 2026. The acetonitrile expansion is also progressing for commissioning in FY2026-27.
Outlook for EV-Based Products and Demand Ramp-up
Balaji Amines has commissioned electronic grade DMC and battery-grade NMP, with DMC currently operating at 20% capacity for other applications. However, the ramp-up of domestic EV battery manufacturers has been slower than anticipated, impacting full utilization. Management expects bulk demand from EV players to commence from December 2025 or April 2026, as they await the industry's 'kick start'.
Future Growth Projections and Margin Guidance
Management anticipates a gradual improvement in performance, projecting a minimum 8% to 10% volume growth in H2 FY26. For the next financial year (FY27), a minimum 15% growth in both values and volumes is expected, assuming optimal capacity utilization. The sustainable EBITDA margin is guided to be in the range of 20% to 22% in the near term, with a floor of 17.5-18% and a potential maximum of 24%.
Raw Material and Competitive Landscape
Raw material prices, particularly methanol and ammonia, have shown volatility but have recently started settling at lower levels (methanol below INR30, ammonia around INR47-48). This trend is expected to improve margins and boost export opportunities. While the company faces some pricing pressure from Chinese imports, mainly for dimethylformamide, it generally maintains competitiveness across its diversified product portfolio.
Green Chemistry Initiatives and Subsidiary Progress
Balaji Amines is committed to green chemistry, with approximately 80% of its manufacturing now powered by solar energy through rooftop installations and a dedicated solar park. The subsidiary, Balaji Specialty Chemicals Limited, is making steady progress on its INR750 crores expansion, which includes products like hydrogen cyanide and EDTA, and is expected to significantly contribute to the company's long-term growth and product diversification.